

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

WATSON LABORATORIES, INC.  
Petitioner,

v.

UNITED THERAPEUTICS, CORP.  
Patent Owner.

---

Case IPR2017-01622  
Patent 9,339,507 B2

---

Before TONI R. SCHEINER, ERICA A. FRANKLIN, and  
DAVID COTTA, *Administrative Patent Judges*.

COTTA, *Administrative Patent Judge*.

ORDER

Granting Joint Motion to Terminate the Proceeding After Institution and  
Request to Treat Settlement Agreement as Business Confidential  
Information

*37 C.F.R. §§ 42.71; 42.74*

On August 21, 2018, the parties filed a joint motion to terminate the proceeding under 35 U.S.C § 317. Paper 63. In addition, citing to 35 U.S.C § 317(b) and 37 C.F.R. § 42.74, the parties filed a copy of their written settlement agreement, Ex. 2212, and a joint request that the settlement agreement be treated as business confidential information and kept separate from the files of IPR2017-1622 and the patent involved therein. Paper 61.

In the joint motion, the parties explain that termination of the proceeding is appropriate because they have reached an agreement settling their dispute with respect to U.S. Patent No. 9,339,507 B2. Paper 63, 2. The parties also explain that they have agreed to dismiss all other proceedings related to the challenged patent, including the related district court litigation, *United Therapeutics Corp. v. Watson Laboratories, Inc.*, Civil Action No. 3:15-05723-PGS-LHG (D.N.J.). *Id.*

Under these circumstances, we determine that it is appropriate to enter judgment terminating this proceeding. Additionally, we grant the parties' request for the settlement agreement to be treated as business confidential information and kept separate from the file of U.S. Patent No. 9,339,507 B2.

Accordingly, it is

ORDERED that the joint motion to terminate the proceeding is *granted*; and

FURTHER ORDERED that the joint request that the settlement agreement, Ex. 2212, be treated as business confidential information and kept separate from the file of the involved patent under the provisions of 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c) is *granted*; and

FURTHER ORDERED that the proceeding is *terminated*.

IPR2017-01622  
Patent 9,339,507 B2

PETITIONER:

Michael K. Nutter  
Andrew R. Sommer  
Kurt A. Mathas  
WINSTON & STRAWN LLP  
mnutter@winston.com  
asommer@winston.com  
kmathas@winston.com

PATENT OWNER:

Stephen B. Maebius  
George Quillin  
FOLEY & LARDNER LLP  
smaebius@foley.com  
gquillin@foley.com

Shaun R. Snader  
UNITED THERAPEUTICS CORP.  
ssnader@unither.com

Douglas Carsten  
Richard Torczon  
Robert Delafield  
Veronica Ascarrunz  
WILSON, SONSINI, GOODRICH & ROSATI  
dcarsten@wsgr.com  
rtorczon@wsgr.com  
bdelafield@wsgr.com  
vascarrunz@wsgr.com